Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974519 | 1.00 | ATR (0.35) | ATRADRB2ADRB1ADRB3BACE1 | |
| SCHEMBL6432910 | 0.82 | ADRB1 (0.32) | ADRB2ADRB1ADRB3BACE1CASR | |
| SCHEMBL6436830 | 0.82 | ADRB1 (0.42) | ADRB2ADRB1ADRB3BACE1CASR | |
| SCHEMBL6432906 | 0.82 | ADRB1 (0.32) | ADRB2ADRB1ADRB3BACE1CASR | |
| SCHEMBL6436834 | 0.82 | ADRB1 (0.40) | ADRB2ADRB1ADRB3 | |
| SCHEMBL6434526 | 0.82 | CYP1A2 (0.35) | CKS1BSKP1SKP2 | |
| SCHEMBL6433084 | 0.82 | ADRB1 (0.42) | ADRB2ADRB1ADRB3BACE1 | |
| SCHEMBL6434534 | 0.82 | CYP1A2 (0.35) | CKS1BSKP1SKP2 | |
| SCHEMBL6435848 | 0.81 | ADRB1 (0.45) | ADRB2ADRB1ADRB3CASR | |
| SCHEMBL6432460 | 0.81 | ADRB3 (0.52) | ADRB2ADRB1ADRB3CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001042217-A1 | BETA-3 ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |